Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC
About this episode
Jorge Nieva, MD discusses the management of toxicity in patients with advanced EGFR-mutated NSCLC and the importance of shared decision making.
Combination regimens improve survival in advanced EGFR-mutated NSCLC, but they also increase toxicity. Jorge Nieva, MD, shares how he talks with patients about potential adverse events. Hedescribes the options available for prophylaxis and how he treats the toxicities that do arise.
People in this episode
Host: Oncology News Central
Guest: Jorge Nieva, MD
Topics covered
- shared decision making
- toxicity management
- EGFR-mutated NSCLC
- patient communication
- adverse events
- prophylaxis options
Keywords
- EGFR
- NSCLC
- toxicity
- adverse events
- prophylaxis
- patient communication
- survival
- combination regimens
Mentioned in this episode
Organizations: Oncology News Central
Books & works: EGFR- Mutated Advanced NSCLC
More episodes of Oncology News Central Peer-Spectives
- New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target”
- Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic
- Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care
- “Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions
- “Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm NSCLC
- As Terminal Patients Live Longer, How Can Oncologists Help Them Cope With Uncertainty?
Explore listener stats, chart rankings, contacts and more on the Oncology News Central Peer-Spectives podcast page.